Vigonvita Life Sciences Co., Ltd. (HKG:2630)

Market Cap	12.79B
Revenue (ttm)	250.82M +8.8%
Net Income	-351.85M
EPS	-2.19
Shares Out	167.60M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,000
Open	76.30
Previous Close	76.80
Day's Range	76.30 - 76.30
52-Week Range	51.00 - 134.90
Beta	n/a
Analysts	n/a
Price Target	n/a
Est. Earnings	Nov 27, 2026

About Vigonvita Life Sciences

Vigonvita Life Sciences Co., Ltd., a biopharmaceutical company, engages in the discovery, development, and commercialization of small molecule drugs for neuropsychiatry, reproductive health, and viral infection therapeutic areas. Its products include LV232, a first-in-class dual-target 5-HTT/5-HT modulators, which is in Phase II of clinical trial for the treatment of depressive disorder; and TPN171, a type-5 phosphodiesterase inhibitor completed Phase III clinical trial for the treatment of erectile dysfunction. The company also develops VV116,...

• Industry: Drug Manufacturers - General
• Sector: Healthcare
• Founded: 2013
• Employees: 351
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 2630

Financial Performance

In 2025, Vigonvita Life Sciences's revenue was 102.10 million, an increase of 762.88% compared to the previous year's 11.83 million. Losses were -355.72 million, 68.3% more than in 2024.

Financial numbers in CNY

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Oct 28, 2026

Data Sources Report a data error